Bevacizumab combined with chemotherapy and anti-PD-1 therapy for the first-line treatment of previously untreated metastatic triple-negative breast cancer

Bevacizumab combined with chemotherapy and anti-PD-1 therapy for the first-line treatment of previously untreated metastatic triple-negative breast cancer

Saved in:

Bibliographic Details
Main Author:	Bi-Cheng Wang
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2025-04-01
Series:	Journal for ImmunoTherapy of Cancer
Online Access:	https://jitc.bmj.com/content/13/4/e012312.full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Bevacizumab, tislelizumab and nab-paclitaxel for previously untreated metastatic triple-negative breast cancer: a phase II trial
by: Wei Yang, et al.
Published: (2025-04-01)

Cost-effectiveness analysis of pembrolizumab plus chemotherapy versus placebo plus chemotherapy for patients with previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer in China
by: Yibing Hou, et al.
Published: (2025-08-01)

Metronomic Chemotherapy in Triple-Negative Metastatic Breast Cancer: The Future Is Now?
by: M. E. Cazzaniga, et al.
Published: (2017-01-01)

Phase 2 Trial of Combination Radiotherapy and Pembrolizumab Plus Chemotherapy in Patients With Previously Untreated Metastatic NSCLC: NJLCG 1902
by: Yoko Tsukita, MD, PhD, et al.
Published: (2025-05-01)

Efficacy of Adding Bevacizumab in the First-Line Chemotherapy of Metastatic Colorectal Cancer: Evidence from Seven Randomized Clinical Trials
by: Yan-xian Chen, et al.
Published: (2014-01-01)

Natural history and prognostic nomogram of untreated triple negative breast cancer based on SEER database
by: Dasong Wang, et al.
Published: (2025-07-01)

Atezolizumab plus bevacizumab and chemotherapy versus bevacizumab plus chemotherapy for metastatic cervical cancer: a cost-effectiveness analysis
by: Hongfu Cai, et al.
Published: (2024-10-01)

A phase 2 study of tislelizumab combined with bevacizumab and chemotherapy as first-line treatment for persistent, recurrent, or metastatic cervical cancerResearch in context
by: Qiang Wen, et al.
Published: (2025-07-01)

Chemoimmunomodulation in triple negative breast cancer: a key to maximizing anti-PD-1 chemoimmunotherapeutic efficacy
by: Mohammed O. Gbadamosi, et al.
Published: (2025-12-01)

Metastatic Triple Negative Breast Cancer: The New Era of Thinking
by: Mohammed Amrallah A., et al.
Published: (2021-05-01)

Ipatasertib combined with non-taxane chemotherapy for patients with previously treated advanced triple-negative breast cancer: the PATHFINDER phase IIa trial
by: Elena López-Miranda, et al.
Published: (2025-08-01)

Efficacy and safety of bevacizumab in combination with irinotecan and capecitabine in first-line treatment of metastatic colorectal carcer
by: Jungić Saša, et al.
Published: (2017-01-01)

Efficacy and Safety of PD-1/PD-L1 Inhibitors in Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis
by: Zhen-Yu Li, et al.
Published: (2023-09-01)

The efficacy and immune-mediated safety of PD-1/PD-L1 combined with neoadjuvant chemotherapy in triple-negative breast cancer: a meta-analysis
by: Xiao Yan, et al.
Published: (2025-08-01)

An immunomodulatory photosensitizer-mediated photodynamic therapy synergizes with PD-L1 blockade against metastatic triple-negative breast cancer
by: Yuetong Liu, et al.
Published: (2025-07-01)

Alternating modified CAPOX/CAPIRI plus bevacizumab in untreated unresectable metastatic colorectal cancer: a phase 2 trial
by: Sheng Li, et al.
Published: (2024-12-01)

Clinical case of torpid course of metastatic triple negative breast cancer
by: E. P. Kulikov, et al.
Published: (2022-03-01)

Cost-effectiveness of NALIRIFOX versus Nab-paclitaxel and gemcitabine in previously untreated metastatic pancreatic ductal adenocarcinoma
by: Wenjie Liu, et al.
Published: (2025-04-01)

Associations of blood RNA biomarkers and circulating tumour cells in patients with previously untreated metastatic colorectal cancer
by: Manuel Valladares-Ayerbes, et al.
Published: (2025-04-01)

Triple therapy revolutionizes treatment paradigms for previously untreatable HCC complicated by high-flow hepatic arteriovenous fistulas
by: Jinpeng Li, et al.
Published: (2025-08-01)

Aumolertinib plus bevacizumab for untreated advanced NSCLC with EGFR sensitive mutation
by: Lingping Kong, et al.
Published: (2025-06-01)

PD-1/PD-L1 immune checkpoint inhibitors in the treatment of unresectable locally advanced or metastatic triple negative breast cancer: a meta-analysis on their efficacy and safety
by: Zuxiu Wang, et al.
Published: (2024-10-01)

Targeted Treatment of Metastatic Triple-Negative Breast Cancer: A Systematic Review
by: Anna Martha Hammershøi Madsen, et al.
Published: (2024-01-01)

Progress of PD-1/PD-L1 immune checkpoint inhibitors in the treatment of triple-negative breast cancer
by: Hongshu Li, et al.
Published: (2025-04-01)

Correction: Triple therapy revolutionizes treatment paradigms for previously untreatable HCC complicated by high-flow hepatic arteriovenous fistulas
by: Jinpeng Li, et al.
Published: (2025-08-01)

Atezolizumab plus bevacizumab and chemotherapy as first-line therapy for cervical cancer: a cost-effectiveness analysis in the US
by: Yingtao Lin, et al.
Published: (2024-11-01)

COMPARATIVE ANALYSIS OF DIFFERENT NEOADJUVANT CHEMOTHERAPY REGIMENS FOR TRIPLE-NEGATIVE BREAST CANCER
by: P. V. Krivorotko, et al.
Published: (2017-12-01)

Cisplatin as neoadjuvant chemotherapy in triple negative breast cancer: Exciting early results
by: Goel Arun, et al.
Published: (2010-01-01)

TROPION-Breast05: a randomized phase III study of Dato-DXd with or without durvalumab versus chemotherapy plus pembrolizumab in patients with PD-L1-high locally recurrent inoperable or metastatic triple-negative breast cancer
by: Peter Schmid, et al.
Published: (2025-04-01)

Enfortumab vedotin plus pembrolizumab for previously untreated locally advanced or metastatic urothelial carcinoma: a cost-effectiveness analysis
by: Youwen Zhu, et al.
Published: (2025-01-01)

Case Report: Palliative Care for Metastatic triple negative Breast Cancer with Cutaneous Involvement
by: Kaylee Scarnati, et al.
Published: (2025-06-01)

Eribulin Effectiveness and Safety in Metastatic Triple-Negative Breast Cancer: A Narrative Review
by: Herleeyana Meriyani, et al.
Published: (2025-02-01)

Cost-effectiveness analysis of a first-line treatment with cadonilimab plus platinum-based chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer in China: COMPASSION-16 trial
by: Yiling Ding, et al.
Published: (2025-12-01)

Cost-effectiveness analysis of cadonilimab plus bevacizumab and chemotherapy for persistent, recurrent, or metastatic cervical cancer
by: Kaixuan Wang, et al.
Published: (2025-06-01)

Multimodal prediction based on ultrasound for response to neoadjuvant chemotherapy in triple negative breast cancer
by: Maohua Lyu, et al.
Published: (2025-07-01)

NIVO-TIL: combination anti-PD-1 therapy and adoptive T-cell transfer in untreated metastatic melanoma: an exploratory open-label phase I trial
by: Jean-Matthieu L'Orphelin, et al.
Published: (2024-11-01)

Comparison of first-generation EGFR-TKIs combined with low-dose bevacizumab versus osimertinib in untreated advanced EGFR-mutated NSCLC
by: Yingqi Xu, et al.
Published: (2025-12-01)

MMP14 and DDR2 are potential molecular markers for metastatic triple-negative breast cancer
by: Rabeah Al-Temaimi, et al.
Published: (2025-07-01)

Responses to checkpoint inhibition in metastatic triple negative breast cancer driven by divergent myeloid phenotypes
by: Avia D. Wilkerson, et al.
Published: (2025-05-01)

Synergistic Induction of Immunogenic Cell Death by Biomineralized Manganese and Bisphosphonates Enhances Anti-PD-L1 Therapy in Triple-Negative Breast Cancer
by: Zhang X, et al.
Published: (2025-04-01)